ABOUT US
“Now that we have witnessed the recent approval of preventive therapies for T1D and revolutionary diabetes technology development, we recognized that the DRI has always been the frontline of T1D. ”
Rodolfo J. Galindo, MD
Position: Associate Professor of Medicine, Director of Comprehensive Diabetes Center, UHealth System
Read more
DRI Affinity Group: Beta cell robustness and augmentation, function enhancement and islet cross talk”or immunology
Dr. Rodolfo J. Galindo graduated from the Institute of Medical Sciences at the University of Havana in 2005. He completed an Internal Medicine residency and Endocrinology fellowship at the Albert Einstein College of Medicine, and North Shore University Hospital, in New York. He then joined the faculty of the Mount Sinai School of Medicine, where he was the Director of the Inpatient Diabetes Service. In 2017, Dr. Galindo joined the faculty of Emory University, to work with his mentor, Dr. Guillermo E. Umpierrez, on clinical investigation in diabetes and obesity. Dr. Galindo is an Associate Professor at the University of Miami.
Research Focus:
Dr. Galindo’s research focuses on clinical trials and patient-oriented observational studies in people with diabetes and obesity, using diabetes technology. His research program has been supported by the NIH, foundations and industry. Dr. Galindo has also served as author of national and international guidelines, including the Consensus Statement on the Use of Diabetes Technology in the Hospital (Diabetes Technology Society, 2020), the AACE Diabetes Mellitus Comprehensive Care Plan (2022), AACE Algorithm for the Management of Type 2 Diabetes (2023), ADA Diabetes Ketoacidosis guidelines (2024), and the ADA Standard of Care for Diabetes guidelines (2023 and 2024).